Form 8-K - Current report:
SEC Accession No. 0001193125-26-218240
Filing Date
2026-05-12
Accepted
2026-05-12 08:08:34
Documents
12
Period of Report
2026-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d24879d8k.htm   iXBRL 8-K 25460
2 EX-99.1 d24879dex991.htm EX-99.1 41525
  Complete submission text file 0001193125-26-218240.txt   188922

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA klrs-20260512.xsd EX-101.SCH 3183
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE klrs-20260512_lab.xml EX-101.LAB 17992
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE klrs-20260512_pre.xml EX-101.PRE 11263
15 EXTRACTED XBRL INSTANCE DOCUMENT d24879d8k_htm.xml XML 3649
Mailing Address 400 CONNELL DRIVE SUITE 5500 BERKELEY HEIGHTS NJ 07922
Business Address 400 CONNELL DRIVE SUITE 5500 BERKELEY HEIGHTS NJ 07922 650-249-2727
Kalaris Therapeutics, Inc. (Filer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39409 | Film No.: 26965956
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)